Cyprotex PLC Director Dealing (9255O)
November 11 2016 - 2:00AM
UK Regulatory
TIDMCRX
RNS Number : 9255O
Cyprotex PLC
11 November 2016
Cyprotex PLC
("Cyprotex" or "the Company")
Director Dealing
Cyprotex PLC (AIM: CRX), a specialist Contract Research
Organisation, announces that it was notified on 10 November 2016
that, on 10 November 2016, Steve Harris, Non-Executive Director,
transferred 80,000 ordinary shares of 1p each in the Company
("Ordinary Shares") from an account in his own name to his wife
Susan Harris for nil consideration by way of a gift. Following this
transfer, Steve Harris' beneficial interest in the Company's
Ordinary Shares remains unchanged at 235,514 Ordinary Shares,
representing 1.05% of the Company's total issued share capital.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -------------------------------------------------------
a) Name Ralph Steve Harris
--- ------------------------- ----------------------------
2 Reason for the notification
--- -------------------------------------------------------
a) Position/status Non- Executive Director of
Cyprotex PLC
--- ------------------------- ----------------------------
b) Initial notification Initial Notification
/Amendment
--- ------------------------- ----------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- -------------------------------------------------------
a) Name Cyprotex PLC
--- ------------------------- ----------------------------
b) LEI N/A
--- ------------------------- ----------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -------------------------------------------------------
a) Description of Ordinary Shares of 1p each
the financial
instrument, type
of instrument
ISIN Code: GB00BP25RZ14
Identification
code
--- ------------------------- ----------------------------
b) Nature of the Transfer of Ordinary Shares
transaction
--- ------------------------- ----------------------------
c) Price(s) and volume(s) Price(s): Volume(s):
N/A 80,000
--- ------------------------- ----------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
--- ------------------------- ----------------------------
e) Date of the transaction 10/11/2016
--- ------------------------- ----------------------------
f) Place of the transaction London Stock Exchange
--- ------------------------- ----------------------------
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad & Broker) Tel: +44 (0)20 7496
3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is quoted on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1500 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling solutions including Cloe(R) PK, chemPK(TM) and
chemTox, and a range of skin, ocular and endocrine disruption
services. For more information, please visit www.cyprotex.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGGGQPGUPQPUU
(END) Dow Jones Newswires
November 11, 2016 02:00 ET (07:00 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Jul 2023 to Jul 2024